Aclarion shares surge 21.28% intraday after Nociscan featured in IJSS special pain issue with case study success.

Aclarion (NASDAQ: ACON) surged 21.28% intraday after multiple news events highlighted its Nociscan solution being featured in the International Journal of Spine Surgery (IJSS) and a record 89% year-over-year increase in Nociscan scan volumes for Q3 2025. The journal publication, a prominent peer-reviewed platform, showcased a successful case study where Nociscan enabled precise diagnosis of chronic low back pain, validating its clinical utility. The technology, described as the first evidence-supported SaaS platform for noninvasive lumbar disc pain assessment, was praised for improving surgical targeting and patient outcomes. The scan volume growth and journal recognition collectively reinforced investor confidence in Aclarion’s market potential and technological differentiation, driving the sharp intraday rally.